Skip to main content

Advertisement

SpringerLink
Log in

Association of tumor necrosis factor–α (G-308A) genetic variant with matrix metalloproteinase–9 activity and joint destruction in early rheumatoid arthritis

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Matrix metalloproteinases (MMPs) are the key enzymes responsible for the joint destruction. Their activity is regulated by the level of proinflammatory cytokines. The aim of this study was to examine the impact of TNF–α G-308A polymorphism on MMP–9 levels in blood plasma (BP) and synovial fluid (SF) of patients with rheumatoid arthritis (RA) and their role in progression of joint destruction. One hundred thirty-four subjects were enrolled in this study. TNF–α G-308A polymorphism was determined using PCR–RFLP method. ELISA assay was used for the detection of MMP–9 activity in BP and SF. Joint damage was estimated by hands and feet radiography. Larsen score and annual changes in LS were used for quantitative evaluation of joint destruction and radiographic progression of disease. MMP–9 activity in BP and SF was significantly higher in RA compared to controls, as well as in SF of patients with erosive compared to nonerosive RA. Faster radiographic progression and increased MMP–9 activity in BP and SF were detected in the group A (GA or AA genotype carriers) compared to the group G (GG genotype carriers). However, statistical significance was revealed only for MMP–9 activity in SF (p < 0.05). MMP–9 activity in BP and SF is significantly higher in RA patients compared to patients with osteoarthritis. The presence of TNF–α-308A allele is associated with increased MMP–9 activity in SF of patients with early RA and may be a predictor of rapid radiographic progression of disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Scott LD, Wolfe F, Huizinga TW (2010) Rheumatoid arthritis. Lancet 376:1094–1108

    Article  PubMed  Google Scholar 

  2. Huet G, Filipo RM, Colin C, Janin A, Hemon B, Collyn-d'Hooghe M (1993) Stimulation of the secretion of latent cysteine proteinase activity by tumor necrosis factor alpha and interleukin 1. Arthritis Rheum 36:772–780

    Article  CAS  PubMed  Google Scholar 

  3. Chan KK, Hee LC (2005) MAP kinase activation is required for the MMP-9 induction by TNF-stimulation. Arch Pharm Res 28(11):1257–1262

    Article  Google Scholar 

  4. Rodrigez-Lopez J, Perez Pampin E, Gomez Reino JJ, Gonzalez A. (2006) Regulatory polymorphisms in extracellular matrix protease genes and susceptibility to rheumatoid arthritis: a case-control study. Arthritis Res Ther (8)1:R1.

  5. Kawakami A, Eguchi K (2002) Involvement of apoptotic cell death in autoimmune disease. Medical Electron Microscopy 35(1):1–8

    Article  CAS  PubMed  Google Scholar 

  6. Scherer S, Barboza de Souza T, de Paoli J, Viegas Brenol C, Machado Xavier R, Tavares Brenol CJ et al (2010) Matrix matalloproteinase gene polymorphism in patients with rheumatoid arthritis. Rheumatol Int 30:369–373

    Article  CAS  PubMed  Google Scholar 

  7. Demeter J, Porzsolt F, Ramish S, Schmidt D, Schmid M, Messer G (1997) Polymorphism of the tumor necrosis factor-alpha and lymphotoxin-alpha genes in chronic lymphocytic leukaemia. Br J Hematol 97(1):107–112

    Article  CAS  Google Scholar 

  8. Larsen A (1995) How to apply Larsen score in evaluating radiographs of rheumatoid arthritis in long-term studies. J Rheumatol 22:1974–1975

    CAS  PubMed  Google Scholar 

  9. Matsuda Y, Yamanaka H, Higami K, Kasgiwazaki S (1998) Time lag between active joint inflammation and radiological progression in patients with early rheumatoid arthritis. J Rheumatol 25:427–432

    CAS  PubMed  Google Scholar 

  10. Wolfe F, Sharp JT (1998) Radiographic outcome of recent-onset rheumatoid arthritis: a 19 year study of radiographic progression. Arthritis Rheum 41:1571–1582

    Article  CAS  PubMed  Google Scholar 

  11. Stojanovic S (2005) Predictors of prognosis of rheumatoid arthritis. Medical Faculty, University of Nis, Master Thesis

    Google Scholar 

  12. Lipsky PE, van der Heijde DMFM, St Clair EW, Furst DE, Breedveld FC, Kalden JR et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 343:1594–1602

    Article  CAS  PubMed  Google Scholar 

  13. Padyukov L, Lampa J, Heimburger M, Ernestam S, Cederholm T, Lundkvist I et al (2003) Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis 62:526–552

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Cuchacovich M, Soto L, Edwardes M, Gutierrez M, Llanos C, Pacheco D et al (2006) Tumour necrosis factor (TNF)alpha−308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis. Scand J Rheumatol 35:435–440

    Article  CAS  PubMed  Google Scholar 

  15. Miceli-Richard C, Comets E, Verstuyft C, Tamouza R, Loiseau P, Ravaud P et al (2008) A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis. Ann Rheum Dis 67:478–484

    Article  CAS  PubMed  Google Scholar 

  16. Seitz M, Wirthmuller U, Moller B, Villiger PM (2007) The −308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology 46:93–96

    Article  CAS  PubMed  Google Scholar 

  17. Dennis G Jr, Holweg CTJ, Kummerfeld SK, Choy DF, Setiadi F, Hackney JA et al (2014) Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics. Arthritis Res Ther 16:R90

    Article  PubMed  PubMed Central  Google Scholar 

  18. de Jong TD, Vosslamber S, Verweij CL (2014) Moving towards personalized medicine in rheumatoid arthritis. Arthritis Res Ther 16(3):110

    Article  PubMed  PubMed Central  Google Scholar 

  19. Tchetverikov I, Lard LR, De Grot JD, Verzijl N, TeKoppele JM, Breedveld FC et al (2003) Matrix metaloproteinases -3,-8,-9 as marker of disease activity and joint damage progression in early rheumatoid arthritis. Ann Rheum Dis 62:1094–1099

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Ahrens D, Koch AE, Pope RM, Stein-Picarella M, Neidbala MJ (1996) Expression of matrix metalloproteinase 9 (96 kdgelatinase B) in human rheumatoid arthritis. Arthritis Rheum 39:1576–1587

    Article  CAS  PubMed  Google Scholar 

  21. Tchetverikov I, Lohmander LS, Verzijl N, Huizinga TW, TeKoppele JM, Hanemaaijer R, De Groot J (2005) MMP protein and activity levels in synovial fluid from patients with joint injury, inflammatory arthritis and osteoarthritis. Annals of the Rheumatic Disease 64:694–698

    Article  CAS  Google Scholar 

  22. Yamanaka H, Matsuda Y, Tanaka M, Sendo W, Nakajima H, Taniguchi A, Kamatani N (2000) Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis & Rheumatism 4:852–888

    Article  Google Scholar 

  23. Hirata S, Tanaka Y (2016) New assessment method in rheumatoid arthritis. Nihon Rinsho 74(6):931–937

    PubMed  Google Scholar 

  24. Hambardzumyan K, Bolce R, Saevarsdottir S, Cruickshank SE, Sasso EH, Chernoff D et al (2015) Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial. Ann Rheum Dis 74(6):1102–1109

    Article  CAS  PubMed  Google Scholar 

  25. Hirata S, Li W, Kubo S, Fukuyo S, Mizuno Y, Hanami K et al (2016) Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice. Mod Rheumatol 26(6):850–856

    Article  CAS  PubMed  Google Scholar 

  26. Burrage PS, Mix KS, Brinckerhoff CE (2006) Matrix metalloproteinases: role in arthritis. Front Biosci 11:529–543

    Article  CAS  PubMed  Google Scholar 

  27. Boman A, Kokkonen H, Ärlestig L, Berglin E, Rantapää-Dahlqvist S (2017) Receptor activator of nuclear factor kappa-B ligand (RANKL) but not sclerostin or gene polymorphisms is related to joint destruction in early rheumatoid arthritis. Clin Rheumatol. doi:10.1007/s10067-017-3570-4

  28. Cordiali-Fei P, Trento E, D' Agosto G, Bordignog V, Mussi A, Ardigo M et al. (2006) Decreased levels of mataloproteinase-9 and angiogenic factors in skin lesions of patients with psoriatic arthritis after therapy with anti TNF-α. Journal of Autoimmune Disease 3: 5–12.

  29. Sallack N, Akcurin G, Koksay S et al (2005) TNF alpha G-308A polymorphism is associated with rheumatic fever and correlates with increased TNF-alpha production. J Autoimmun 25:150–154

    Article  Google Scholar 

  30. Demacq C, Vasconcellos V, Marcaccini A, Gerlach R, Silva W Jr, Tanus-Santos J (2008) Functional polymorphism in the promoter of the matrix metalloproteinase-9 (MMP-9) gene are not linked with significant plasma MMP-9 variation in healthy subjects. Clin Chem Lab Med 46:57–63

    Article  CAS  PubMed  Google Scholar 

  31. Basic J, Pavlovic D, Jevtovic-Stoimenov T, Vojinovic J, Susic G, Stojanovic I et al (2010) Etanercept reduces matrix metalloproteinase-9 level in children with polyarticular juvenile idiopathic arthritis and TNF-alpha-308 GG genotype. J Physiol Biochem 66(2):173–180

    Article  CAS  PubMed  Google Scholar 

  32. Mouterde G, Lukas C, Logeart I, Flipo RM, Rincheval R, Daures JP, Combe B (2011) Predictors of radiographic progression in the ESPOIR cohort: the season of first symptoms may influence the short-term outcome in early rheumatoid arthritis. Annals of the Rheuamtic Diseases 70:1251–1256

    Article  CAS  Google Scholar 

  33. Pejović M, Stanković A, Mitrović D, Dimić A, Lović B (1996) Concentration of albumin, total and four acute phase proteins in the serum and synovial fluid of patients suffering from osteoarthritis and rheumatoid arthritis. Facta Universitatis 1:19–23

    Google Scholar 

Download references

Acknowledgments

This work was supported by the Ministry of Education, Science and Technological Development of the Republic of Serbia (grant number III41018, 2011-2016).

Author information

Authors and Affiliations

  1. Institute “NiskaBanja”, Faculty of Medicine, University of Nis, Nis, Serbia

    Sonja Stojanovic,  Bojana Stamenkovic & Valentina Zivkovic

  2. Department of Biochemistry, Faculty of Medicine, University of Nis, Nis, Serbia

    Tatjana Jevtovic Stoimenov, Milena Despotovic & Dusica Pavlovic

  3. Institute “NiskaBanja”, NiskaBanja, Serbia

    Jovan Nedovic

Authors
  1. Sonja Stojanovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bojana Stamenkovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tatjana Jevtovic Stoimenov
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jovan Nedovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Valentina Zivkovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Milena Despotovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Dusica Pavlovic
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sonja Stojanovic.

Ethics declarations

All participants signed an informed consent before they entered the study. The study was approved by the Ethical committee of the Faculty of Medicine, University in Nis, Serbia, and the Ethical committee of the Institute “Niska Banja”, Nis, Serbia. The study was conducted according to the ethical standards given in the Declaration of Helsinki.

Disclosures

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stojanovic, S., Bojana Stamenkovic, Stoimenov, T.J. et al. Association of tumor necrosis factor–α (G-308A) genetic variant with matrix metalloproteinase–9 activity and joint destruction in early rheumatoid arthritis. Clin Rheumatol 36, 1479–1485 (2017). https://doi.org/10.1007/s10067-017-3699-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-017-3699-1

Keywords

Search

Navigation